Scientists Identify Gentler Strategy To Prevent Gum Disease While Preserving “Good” Oral Bacteria

IMT News Desk
IMT News Desk
· 2 min read
Scientists have discovered a gentler way to prevent gum disease by blocking how harmful bacteria communicate

Scientists have identified a potential new way to prevent gum disease by disrupting how harmful bacteria communicate, instead of killing all microbes in the mouth. The research shows that dental plaque bacteria use chemical signals to coordinate their growth, and when these signals are blocked, disease-linked microbes decrease while health-associated bacteria increase.

The work, led by researchers from the College of Biological Sciences and the School of Dentistry in the US, focused on signalling molecules known as N-acyl homoserine lactones (AHLs), which help bacteria “talk” to each other in both oxygen-rich areas above the gumline and oxygen-poor areas below it. Using specialised enzymes called lactonases to remove AHL signals in laboratory biofilms, the team observed a shift toward bacterial species associated with good oral health, suggesting that carefully selected enzymes could be used to reshape dental plaque communities and maintain a healthier oral microbiome.

Current treatments for gum disease often rely on mechanical cleaning or broad-spectrum antimicrobials that can damage beneficial bacteria and may contribute to antibiotic resistance. By contrast, this signalling-based strategy aims to maintain microbial balance rather than sterilise the mouth, potentially offering a gentler, more sustainable approach to preventing periodontal disease. Researchers say that understanding and targeting bacterial “quorum sensing” could open the door to new oral care products that reduce the risk of gum disease while preserving the protective functions of good bacteria.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk